EchoSolv AS

EchoSolv AS is a cloud-based artificial intelligence and machine learning software designed as an adjunct decision support tool for cardiologists, leveraging patient demographics and echocardiogram data to provide a probabilistic assessment of Severe Aortic Stenosis. Its development and marketing authorization, based on substantial equivalence, underscore its potential to enhance diagnostic processes while operating under stringent Class II medical device regulatory controls.

EchoSolv AS, developed by Echo IQ Ltd., is a newly cleared cloud-based, artificial intelligence and machine learning software intended as a decision support tool for board-certified cardiologists. Its primary purpose is to aid in the diagnosis of Severe Aortic Stenosis (AS) by analyzing patient demographic data combined with measurements derived from transthoracic echocardiograms. The software provides a categorical assessment (high, medium, or low probability) of a Severe AS phenotype and evaluates findings against current clinical practice guidelines, serving as an adjunct for adult patients undergoing echocardiograms for structural heart disease, not as the sole basis for patient management decisions. This device has received marketing authorization based on a determination of substantial equivalence to existing products, classifying it as a Class II medical product. As such, EchoSolv AS is subject to ongoing general controls, including annual registration, device listing, adherence to good manufacturing practices, truthful labeling, quality system regulations (like design controls), the Unique Device Identification System (UDi Rule), and medical product reporting for adverse events. The substantial equivalence determination was based on non-clinical and clinical performance data, which demonstrated the device met established specifications and did not raise new safety or effectiveness concerns, though this status does not imply compliance with all other federal statutes or regulations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific AI/ML algorithms does EchoSolv AS employ to derive its probability assessments for Severe AS?; How does the integration of patient demographic data with echocardiogram measurements enhance diagnostic accuracy compared to traditional methods?; What were the key findings from the non-clinical and clinical performance data that supported the determination of substantial equivalence, particularly regarding sensitivity, specificity, and predictive values?; How does EchoSolv AS differentiate itself from existing decision support tools for AS, and what unique benefits does it offer to cardiologists?; What post-market surveillance plans are in place to monitor the long-term effectiveness, safety, and real-world performance of EchoSolv AS in diverse patient populations?